Clinical Trial Search

Primary: Percent Change in Brachial Artery Flow-mediated Dilation at Each Time Point — 4.11; 6.93; 5.86; 3.20 Percent Change

Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation

Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1

Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight

Primary: Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD) — 5.49; 3.39 % FMD after 6 weeks of treatment — p=0.04

Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass

Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale

Primary: Collagen Type 1 C-telopeptide — 0.4; 0.4; 0.3; 0.4 ng/ml

Primary: Progression of Subclinical Atherosclerosis — 4.77; 5.68 um/year — p=0.35

Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI

Primary: Change From Baseline in Circulating Lycopene Levels — 2.85 umol/L

Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05

Primary: Vascular Endothelial Function — -307; -34.8; -36.8; -110 %*min

Primary: Blood Pressure (mmHg) — 122; 116 mmHg

Primary: Change in Mean Systolic and Diastolic Blood Pressure (mm/Hg) From Baseline (Time 1) to Time 2 — -0.3; -2.4; 1.2; 2.2 mmHg

Primary: Cutaneous Conductance (%Maximum) Response to Acetylcholine — 89.4; 72.5 % of maximal cutaneous conductance

Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day

Primary: Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV) — -1.9; -1.7 m/s

Primary: Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up — 2; 1; 1; 5…

Primary: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells — 17.50; 16.72; 23.20; 5.63 percentage of vaginal superficial cells — p=< 0.0001

Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein

Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow

Primary: Resting Aortic Blood Pressures — 113.3; 116.9 mmHg

Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003

Primary: Ten Year Risk of Cardiovascular Disease (CVD) — 2.9 percentage of risk

Primary: Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies — 0; 0; 0; 0 percentage of participants

Primary: Vascular Endothelial Function — -195.9; -6.181; -5.629 %*min

Primary: Blood Epinephrine Levels — 39.3; 46.2 pg/mL

Primary: Immunohistochemistry (IHC) Proliferative Effects Measurement — 0.73; 0.43; 0.25 Square root of % positive stained cells — p=<0.001

Primary: Carotid Femoral Pulse Wave Velocity (cfPWV) — 8.71; 7.8; 8.28 m/s